Observational studyBMC musculoskeletal disorders2025
Comorbidities in spinal muscular atrophy and their impact on the course of the underlying disease: a real-life observational study.
Observational study in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multisystem Complications in Spinal Muscular Atrophy Type III: Chronic Respiratory Failure and Intractable Epilepsy.Cureus · 2026Article
- Spinal muscular atrophy in the disease-modifying therapy era: successes, limitations and future directions.Frontiers in molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lack of the SMN protein in SMA affects different tissues and organs, not only alpha motoneurons; this creates a broad spectrum of potential concomitant diseases, making SMA a multidisciplinary problem. This study focuses on an analysis of comorbidities, and their frequence and severity in SMA.
methodsThe study group consisted of 55 patients, 25 women and 30 men, with genetically confirmed SMA types 2, 3a, and 3b. A medical history focused on comorbidities and a neurological examination with the evaluation on the extended Hammersmith Functional Motor Scale (HFMSE). The prevalence and severity of comorbidities were assessed using the Cumulative Illness Rating Scale (CIRS).
resultsSMA type 2 was associated with the highest mean number of comorbidities and CIRS scores. All patients with type 2 had scoliosis. When scoliosis was not included in the analyses, there were no significant differences in the prevalence of comorbidities and CIRS scale scores between the SMA groups. CIRS scale scores with and without scoliosis were significantly higher in patients with low HFSME scores. Male patients had a greater tendency to develop lithiasis.
conclusionsScoliosis is a major factor that has an influence on the clinical course of SMA and on patients' overall condition. Other comorbidities are similar in all types of SMA. Comorbidities are more frequent and have a greater impact on the general condition in patients with more severe disabilities. The current difference between the sexes is the higher incidence of lithiasis and overweight in men.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.